Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risotilide SCHEMBL635829 | 0.99 | LMNA (0.49) | TRPV4LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL10777217 | 0.86 | TRPV4 (0.51) | TRPV4LMNAMEN1KMT2ACA12 | |
| SCHEMBL8864040 | 0.84 | CYP2C9 (0.44) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL9834718 | 0.83 | RORC (0.46) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL10778015 | 0.81 | TRPV4 (0.52) | TRPV4CA12CA1CA2CA9 | |
| SCHEMBL10627173 | 0.81 | TRPV4 (0.52) | TRPV4HTT | |
| SCHEMBL10778006 | 0.81 | HTT (0.62) | TRPV4LMNAKDM4EMEN1KMT2A | |
| SCHEMBL9835822 | 0.80 | CYP2C9 (0.46) | LMNAADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL10627121 | 0.79 | TRPV4 (0.50) | TRPV4ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL10737899 | 0.78 | TRPV4 (0.49) | TRPV4CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| EP-1086063-A4 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | claimed |
| EP-1086063-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5679706-A | ANTIISCHEMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-21 | — | — | US | claimed |
| EP-0260901-B1 | BENZENESULPHONAMIDES USEFUL AS ANTI-ARRYTHMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| US-4721809-A | Alkylsulfonamido or perfluoroalkylsulfonamido benzenesulfonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | TRPV4 3691/4885LMNA 2248/4885ADRB2 3813/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | TRPV4 3691/4885LMNA 2248/4885ADRB2 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.